06.28.06

Epigenomics to Use Affymetrix Platform

Posted in cancer, news links at 7:10 pm by admin

Epigenomics AG has announced that it will use Affymetrix microarray technology in its in-vitro diagnostic (IVD) tests for oncology and other indications. The Affymetrix technology, along with Epigenomics’ previously announced alliance with Qiagen for sample preparation, will allow for Epigenomics to provide a “complete platform” for its DNA methylation marker pathology tests.

The first use of the Affymetrix platform will be in Epigenomics’ Molecular Classification Test (MCT) for prostate cancer, which is scheduled to begin clinical trials for FDA approval next year. Link